Cumberland Pharmaceuticals Inc. (CPIX)

Overview

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company with a focus on acquiring, developing, and commercializing prescription products targeted at hospital acute care, gastroenterology, and oncology sectors both in the United States and internationally. Since its incorporation in 1999 and with headquarters in Nashville, Tennessee, the company has been committed to addressing the needs of patients with serious or underserved medical conditions through its diverse portfolio of approved products and candidates in development.

Products and Services

• Acetadote - An injectable product designed for the treatment of acetaminophen poisoning, helping to mitigate potentially life-threatening conditions resulting from overdose.
• Caldolor - An injection used for the treatment of pain and fever, providing an alternative route of administration for patients unable to use oral forms of medication.
• Kristalose - A prescription oral solution acting as a laxative for the treatment of constipation, offering a therapeutic option for patients with this condition.
• Omeclamox-Pak - Designed for the treatment of Helicobacter pylori infection and duodenal ulcer disease, this product aims to eradicate H. pylori bacteria, known to cause peptic ulcers.
• Vaprisol - An injectable solution for treating euvolemic and hypervolemic hyponatremia, addressing electrolyte imbalance in the body.
• Sancuso - An injection provided for the management of side effects caused by chemotherapy treatments, specifically to control nausea and vomiting.
• Vibativ - An injection formulated for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
• RediTrex - Currently under development, this injectable medication is aimed at treating active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and disabling psoriasis.

In addition to these products, Cumberland Pharmaceuticals is actively engaged in the development of ifetroban, a versatile product candidate undergoing phase II clinical trials for various conditions, including aspirin-exacerbated respiratory disease, systemic sclerosis, Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and progressive fibrosing interstitial lung diseases.